**Core tip:** Magnetic resonance imaging (MRI) to determine the stage of rectal cancer has been shown to be accurate and reproducible. The patients who showed MRI-detected extramural vascular invasion (EMVI) positivity had worse survival outcomes than those with EMVI negativity. However, the survival rates of patients with an EMVI-positive histology varies dramatically, which suggests that this factor does not relate to each individual tumor in terms of the biology or molecular features. The ideal staging system evolves from the consideration of them and the correlation of the prognosis with patient-specific tumor biomarkers. In this study, we hypothesized that the combination of imaging evidence of EMVI and biomolecular factors could provide additional predictive value in clinical practice, especially for non-advanced cancer patients.

INTRODUCTION
============

The transanal approach may be used to effectively excise rectal carcinoma (RC), which is usually found in the lower part of the rectum. Transanal excision of RCs, however, may be associated with poor locoregional control\[[@B1],[@B2]\] .Therefore, accuracy of preoperative staging is vital in modern rectal cancer management. Magnetic resonance imaging (MRI) to determine the stage of rectal cancer has been shown to be accurate and reproducible\[[@B3],[@B4]\]. MRI enables planning for primary tumor resection.

Recent development in MRI provides the distinguishment of extramural vascular invasion (EMVI) prior to surgery being performed\[[@B5]\]. EMVI is described as blood vessels invaded by malignant cells surpassing the muscularis propria of rectal cancer\[[@B6]\]. Chand et al\[[@B7]\] showed that EMVI leads to worse survival outcomes\[[@B6]\]. However, the survival rates of patients with an EMVI-positive histology varies dramatically, which suggests that this factor does not relate to each individual tumor in terms of the biology or molecular features.

The ideal staging system will evolve from the consideration of them and the correlation of the prognosis with patient-specific tumor biomarkers\[[@B8],[@B9]\]. Based on previous studies, we hypothesized that the combination of imaging evidence of EMVI and biomolecular factors could provide additional predictive value in clinical practice, especially for non-advanced cancer patients.

In this study, three candidate proteins were screened in paraffin-embedded tissue samples *via* immunohistochemistry (IHC). When combined with MRI-detected EMVI, this panel could help clinicians determine the prognosis for patients with RC without regional lymph node involvement and distant metastasis.

MATERIALS AND METHODS
=====================

Patients and tissue specimens
-----------------------------

This study was approved by the institutional review board of Harbin Medical University, and consent was obtained from all of the patients in written form. Patients with pathologically confirmed rectal adenocarcinoma who were treatment-naïve were screened in this research, and were examined through preoperative rectal MRI at the Second Afflict Hospital of Harbin Medical University from July 2011 to July 2014. Patients who were found to have a synchronous regional lymph node and/or distant metastases at the initial staging were excluded from the study. All chosen samples were adopted from the crucial cores of histopathologically confirmed carcinomas during the initial surgeries. Two pathologists performed diagnosis on all of the lesions and the findings were reviewed by an expert colorectal cancer pathologist independently; additionally, the stage of tumor was determined according to the system of the International Union Against Cancer.

MRI protocol
------------

The MRI examination of patients with RC was carried out using a 3.0 T Philips Achieva TX (Philips Medical Systems, Holland) system with an 8-channel body phased array coil. Each rectal magnetic resonance examination was performed as follows: To decrease the colonic motility, an intramuscular injection of 20 mg of scopolamine butylbromide (Buscopan; Boehringer Ingelheim, Germany) was administered prior to the MRI. Approximately 100-120 mL of saline was rectally administered using an enema syringe. High-resolution magnetic resonance images were obtained, including high-resolution oblique axial T2-weighted turbo spin-echo, oblique coronal T2-weighted turbo spin-echo and sagittal T2-weighted turbo spin-echo coupled with the following parameters: TE (echo time) 81 ms-185 ms, TR (repetition time) 3900-5600 ms, thickness of 3 mm, spacing of 3 mm, matrix of 256 × 256 to 320 × 320, field of view of 250 × 250 to 199 × 199, and echo train length of 17-35.

Image analysis
--------------

All magnetic resonance images required at least three abdominal radiologists to analyze the images separately with no clinical information about the patients. The MRI analysis involved tumor morphology, the presence of EMVI, circumferential resection margin, lymph node involvement and tumor stage. The EMVI grading score was adopted from the system proposed by Smith et al\[[@B10]\]. According to this scoring system, scores of 0 to 2 were defined as EMVI-negative disease, and scores of 3 and 4 corresponded to EMVI-positive disease. A score of 3 EMVI included a tumor with a vein that did not change its contour and may have only slightly expanded the vessel. A score of 4 EMVI described an irregularly expanded vein, which indicated the vessel wall was invaded. To achieve a consensus agreement, EMVI negative cases were re-evaluated together by three abdominal radiologists.

IHC
---

To select the study samples, we employed a usual histological categorization according to the WHO classification of tumors. A 3-tiered histological grading system played an important role in this research. The tumor-node-metastasis stage was evaluated, based on the guideline of the 2002 International Union Against Cancer classification. Monoclonal mouse anti-human c-MYC, PCNA and TIMP-1 antibodies were introduced from Santa Cruz Biotechnology (United States). The slides were deparaffinized, rehydrated, immersed in 3% hydrogen peroxide solution for 10 min, heated in citrate buffer (pH 6.0) for 25 min at 95 °C, and cooled for 60 min at room temperature. The slides were washed with PBS (pH 7.4) between each incubation step. Then, the slides were incubated separately with the primary antibodies. Immunoperoxidase staining was performed using the 2-step Envision Method (DAKO, Denmark) abiding by the manufacturer's instructions, and visualized with 3,3 9-diaminobenzidine tetrachloride (Sigma, United States). Negative controls were slides with no primary antibodies.

Cytoplasm and membrane staining were mensurated for the TIMP1 antibody, and c-MYC and PCNA staining showed nuclear localization. Two pathologists counted the positive cells. The scores of the results according to the immunohistochemical staining were obtained with the examiners being completely ignorant of any information related to the patient's clinical data. When it comes to clinicopathological association, the researchers applied a 4-tiered scoring system (negative to 3+), taking into consideration the proportion of positive cells and staining intensity as represented before\[[@B11]\].

Statistical analysis
--------------------

The statistical analyses were carried out *via* the SPSS software program (standard version 19.0; SPSS, United States). The distinctions between groups were determined according to the Mann-Whitney *U* test or the Kruskal-Wallis *H* test. The correlation among categorical data underwent statistical analysis using the *χ^2^* test. Kaplan-Meier curves resulted from the log-rank test for survival analyses. The clinical end point in the research, the period from cancer confirmed to death starting at RC or last contact, was overall survival. Multivariate Cox proportional hazards regression analysis served in the detection of independent prognosticators, which had a conspicuous influence on patient survival. A difference was regarded to be significant under the condition that the *P*-value was less than 0.05.

RESULTS
=======

Characteristics of the study population
---------------------------------------

A total of 329 RC specimens were collected from patients who underwent an operation. The median patient age was 62 years (range, 21-82 years), and the subjects included 122 (37.1%) females and 207 (62.9%) males. All patients underwent curative resection with tumor-free margins. Among all patients, 99 underwent adjuvant chemotherapy. All tumors were histologically diagnosed, graded, and grouped as lowly and moderately differentiated (*n* = 319) or highly differentiated (*n* = 10). The follow-up interval ranged from 1 to 58 mo from the date of diagnosis.

MRI findings
------------

There were 53 cases (16.1%) of EMVI-positive RCs on the initial preoperative MRI scans. Of them, 30 patients (56.6%) had an EMVI score of 3, and 23 patients (43.4%) had an EMVI score of 4. Score 3 MRI-detected EMVI only occurred in small vessels. Score 4 was only observed in medium and large vessels, which was consistent with previous findings\[[@B12]\].

Relationships between protein expression and clinicopathologic characteristics
------------------------------------------------------------------------------

For TIMP1, positive staining was found mainly in the cytoplasm and membrane of the neoplasm cells, and nuclear localization of c-MYC and PCNA was generally observed. Immunostaining of the three proteins was low in some samples but strong in others. Representative examples of IHC expression of TIMP1, c-MYC, and PCNA performed in the study cohorts are shown in Figure [1](#F1){ref-type="fig"}.

![Representative examples of extramural vascular invasion and immunohistochemistry images in distinct prognostic groups. Overexpression of c-MYC and TIMP1 is a marker of better prognosis, whereas PCNA is a marker of poor prognosis, which was consistent with known biological roles.](WJG-22-8576-g001){#F1}

There were no significant differences concerning age, sex, chemotherapy and tumor location. However, a significant association was detected between the expression levels of PCNA, TIMP1 and pT (*P* \< 0.01; *P* = 0.045). Moreover, the overexpression of TIMP1 was associated with the histological grading and perineural invasion (*P* \< 0.01; *P* \< 0.01). Table [1](#T1){ref-type="table"} shows the relationships between the clinicopathological features and protein expression levels.

###### 

Relationship between expression of proteins and clinicopathologic parameters

  **Variable**                       ***n***      **c-MYC expression**         **PCNA expression**        **TIMP1 expression**                         
  ---------------------------------- ------------ ---------------------- ----- --------------------- ---- ---------------------- --------- ----- ----- ---------
  Sex                                                                                                                                                  
  Male                               207          69                     136                         47   160                              119   88    
  Female                             122          49                     73    0.236                 31   81                     0.324     74    48    0.573
  Age, median (range)                62 (21-82)                                                                                                        
  Histology grade, differentiation                                                                                                                     
  Well                               10           4                      6                           2    8                                5     5     
  Moderate                           143          48                     95                          36   107                              57    86    
  Poor                               176          66                     110   0.738                 40   136                    0.844     131   45    \< 0.01
  Pathologic T stage                                                                                                                                   
  T1                                 24           9                      15                          5    19                               11    13    
  T2                                 78           30                     48                          7    71                               41    37    
  T3                                 74           28                     46                          15   59                               53    21    
  T4                                 153          51                     102   0.848                 51   102                    \< 0.01   88    65    0.045
  Lymphovascular invasion                                                                                                                              
  Yes                                153          56                     97                          37   116                              90    63    
  No                                 176          62                     114   0.796                 41   135                    0.850     103   73    0.956
  Perineural invasion                                                                                                                                  
  Yes                                127          45                     82                          32   95                               88    39    
  No                                 202          73                     129   0.897                 46   156                    0.615     105   97    \< 0.01
  Chemotherapy                                                                                                                                         
  Yes                                99           43                     56                          24   75                               58    41    
  No                                 230          75                     155   0.060                 54   176                    0.881     135   95    0.985
  EMVI                                                                                                                                                 
  Positive                           53           18                     35                          13   40                               32    21    
  Negative                           276          100                    176   0.752                 65   211                    0.878     161   115   0.782
  Location                                                                                                                                             
  Below peritoneal reflection        120          41                     79                          31   89                               71    49    
  At peritoneal reflection           43           22                     21                          4    39                               25    18    
  Above peritoneal reflection        166          55                     111   0.080                 43   123                    0.059     97    69    0.990

*P* value was obtained by *χ^2^* test. EMVI: Extramural vascular invasion.

Independent prognostic value of three-protein IHC panel
-------------------------------------------------------

Due to the fact that it illustrated that the three-protein panel and MRI-detected EMVI was of significant predictive value for survival in the long run, multivariate Cox regression analysis was implemented to decide whether these parameters supplied further information of prognosis independent of known clinicopathologic features which could affect the prognosis. As summarized in Table [2](#T2){ref-type="table"}, each parameter had a prognostic significance independently (*P* \< 0.05). Additionally, the three-protein panel displayed greater significance as an independent prognostic factor (HR = 2.110, 95%CI: 1.631-2.556, *P* \< 0.01). The panel combined with the EMVI status could rank patients in a more accurate way (*P* \< 0.01) (Figure [2](#F2){ref-type="fig"}).

###### 

Multivariate Cox regression analysis of factors predicting survival time of patients without regional lymph node and distant metastasis

  **Variable**                                        **HR**   **95%CI**     ***P* value**
  --------------------------------------------------- -------- ------------- ---------------
  Sex (male *vs* female)                              1.312    0.784-2.159   0.354
  Pathologic T stage (T3-4 *vs* T1-2)                 1.226    0.817-2.657   0.012
  Lymphovascular invasion (yes *vs* no)               1.413    0.716-1.971   0.241
  Perineural invasion (yes *vs* no)                   1.539    0.992-2.321   0.114
  EMVI (positive *vs* negative)                       3.071    2.784-5.754   \< 0.01
  c-MYC expression (low *vs* strong)                  1.138    1.003-2.421   0.032
  PCNA expression (strong *vs* low)                   2.582    1.748-4.373   0.003
  TIMP1 expression (low *vs* strong)                  2.643    1.869-5.821   0.021
  IHC panel (2-3 markers high *vs* 0-1 marker high)   2.110    1.631-2.556   \< 0.01

EMVI: Extramural vascular invasion; IHC: Immunohistochemistry.

![Immunohistochemistry panel combined with magnetic resonance imaging-detected extramural vascular invasion enhanced the accuracy of prognoses for patients with rectal carcinoma. Combination of EMVI and the IHC panel separated patients into distinct prognostic groups (*P* \< 0.01). EMVI: Extramural vascular invasion; IHC: Immunohistochemistry.](WJG-22-8576-g002){#F2}

DISCUSSION
==========

Nowadays, local excision has won growing popularity as a strategy for treating RC in that it removes the necessity for colostomy, lowers the threatening perioperative risks for patients, and ensures optimistic functional outcomes\[[@B13],[@B14]\]. This surgical procedure, however, requires a thorough analysis of its oncologic risks since standard resection protocols used to eliminate the rectum with its surrounding lymph nodes have gained favorable oncologic results, and are considered as the gold standard\[[@B15]\]. Hence, proper preoperative staging is necessary. However, staging remains challenging owing to the variable accuracy and limitations of imaging. Patient-specific tumor biomarkers could function as a useful aid to present clinicopathologic parameters for risk stratification. This study identified a three-protein panel for the prognostic assessment of non-advanced RC patients that could supplement current diagnostic systems.

The c-MYC proto-oncogene encodes a transcription factor that has a vital effect on cell proliferation, differentiation, apoptosis, metabolism, and survival\[[@B16],[@B17]\]. In recent study on adenocarcinoma of the colorectum, patients with a c-MYCGCN gain had low rates of survival compared to those without the gain, which was found to be a poor independent prognostic factor\[[@B18]\]. However, the correlation between expression of c-MYC in colorectal cancer and prognosis was contradicted in previous studies\[[@B19]-[@B21]\]. The conflicting results presumably occurred as c-MYC expression is controlled by a complicated regulatory pathway, engaging multi-interactive activities with other molecules\[[@B22]\]. In the present study, we clarified that c-MYC overexpression determined by IHC solely was significantly linked with higher rates of survival in colorectal cancer patients when evaluated by multivariate analysis.

PCNA, which is a non-histamine nuclear protein, has been confirmed to connect with the degree of malignancy, vascular infiltration, distant metastasis and survival\[[@B23]-[@B25]\]. TIMPs have been proposed to be important inhibitors of tumor invasion of the extracellular matrix based on *in vitro* and animal studies\[[@B26],[@B27]\]. Pellegrini et al\[[@B28]\] put forward that, from the phase of pre-invasive node to the phase of invasion, detections of serum levels of CEA and TIMP1 in colorectal cancer patients simultaneously could serve as markers for disease progression in prognosis and diagnosis.

It has been established that patients may experience a drastically increased risk of distant metastasis, given pathological EMVI at the moment of primary resection\[[@B29]\]. The high-resolution MRI provides the preoperative identification of EMVI\[[@B30]\]; preoperative MRI-detected EMVI status for rectal cancer is a crucial procedure, especially in the screening of patients for neoadjuvant treatment\[[@B31]\]. A microRNA panel has been shown to have considerable clinical value in the early diagnosis of colorectal cancer\[[@B32]\]. Through the current research, we identified a three-protein prognostic panel independent of clinicopathological features. What's more important, the three-protein panel combined with MRI-detected EMVI could rank patients into subgroups with diverse prognoses (*P* \< 0.01), which may benefit clinical intervention.

In conclusion, we have identified a three-protein panel in a considerable number of rectal tissue specimens that determines prognosis with accuracy independent of clinical prognostic parameters, and it has magnificent clinical value for surgical decision-making for treating RC.
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Background
----------

Non-advanced rectal cancer (RC) can be treated using various strategies. Accuracy of preoperative staging is vital for modern management of RC. To accurately classify prognostic risks, this study set out to identify a small, clinically applicable immunohistochemistry (IHC) panel that could be combined with magnetic resonance imaging (MRI)-detected extramural vascular invasion (EMVI) for preoperative prognostic assessment of RC patients.

Research frontiers
------------------

MRI is important for the local staging of rectal cancer, the patients who showed MRI-detected EMVI positivity had worse survival outcomes than the EMVI-negative cases. Few prior reports contain analyses of the combination of imaging evidence of EMVI and biomolecular factors in RC. The results of this study suggest that the three-protein panel of c-MYC, PCNA and TIMP1 combined with MRI-detected EMVI could provide additional prognostic information for preoperative treatment of RC.

Innovations and breakthroughs
-----------------------------

In this study, c-MYC, PCNA and TIMP1 were detected with high expression in 35.9%, 23.7% and 58.7% of tumors, respectively. Significant associations were found between the expression of these proteins and the prognosis (*P* = 0.032, 0.003, 0.021). Applying these three proteins as an IHC panel could be used to classify patients into different subgroups (*P* \< 0.01). Upon adjustment for known survival covariates, including EMVI, the IHC panel remained an independent prognostic factor. The combination of EMVI and the IHC panel could separate patients into distinct prognostic groups (*P* \< 0.01).

Applications
------------

These findings suggest that the three-protein panel of c-MYC, PCNA and TIMP1 combined with MRI-detected EMVI could provide additional prognostic information for preoperative treatment of RC.

Terminology
-----------

EMVI is defined as the presence of malignant cells within the blood vessels beyond the muscularis propria of rectal cancer.
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This is an excellent study about the combination of three-gene immunohistochemical panel and MRI-detected EMVI to assess prognosis in non-advanced rectal cancer patients.
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